Evidence map›Paper›PMID 36514718›Full record

ArticleKidney3602022

The Association of Pre-Transplant C-Peptide Level with the Development of Post-Transplant Diabetes: A Cohort Study.

Amanda J Vinson, Aran Thanamayooran, Bryce A Kiberd, Kenneth West, Ferhan S Siddiqi, Lakshman Gunaratnam, Karthik K Tennankore

Open access · diamondAbstract read
In one paragraph

Article in Kidney360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amanda J VinsonDivision of Nephrology, Department of Medicine, Dalhousie University, Halifax, Canada.ORCID 0000-0002-9345-5252
Aran ThanamayooranDivision of Nephrology, Department of Medicine, Dalhousie University, Halifax, Canada.
Bryce A KiberdDivision of Nephrology, Department of Medicine, Dalhousie University, Halifax, Canada.
Kenneth WestDivision of Nephrology, Department of Medicine, Dalhousie University, Halifax, Canada.
Ferhan S SiddiqiDivision of Endocrinology and Metabolism, Department of Medicine, Dalhousie University, Halifax, Canada.
Lakshman GunaratnamMultiorgan Transplant Program, London Health Sciences Centre, London, Canada.ORCID 0000-0002-8845-1126
Karthik K TennankoreDivision of Nephrology, Department of Medicine, Dalhousie University, Halifax, Canada.ORCID 0000-0002-7919-6709
Dalhousie University · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Post-transplant diabetes mellitus (PTDM) is an important complication after kidney transplantation that results in reduced patient and allograft survival. Although there are established risk factors for PTDM, whether pretransplant C-peptide levels associate with PTDM is unknown. Therefore, in this study, we aimed to examine the association of pretransplant C-peptide levels with PTDM. Methods: This was a cohort study of nondiabetic adult patients who underwent kidney transplant in Nova Scotia, Canada, between January 1, 2016, and March 31, 2021, with fasting C-peptide levels measured before transplant. Multivariable logistic regression was used to determine the association of pretransplant C-peptide (dichotomized around the median) with PTDM at 1 year post transplant. Given the known association between pretransplant obesity and PTDM, we repeated our primary analysis in a cohort restricted to a BMI of 20-35 kg/m Results: The median C-peptide value was 3251 (Q1 2480, Q3 4724); pretransplant C-peptide level was dichotomized at 3000 pmol/L. PTDM occurred in 25 (19%) individuals. Thirty percent of patients in the high and only 2% of patients in the low C-peptide groups developed PTDM ( Conclusions: A pretransplant C-peptide level ≥3000 pmol/L was associated with a nearly 20-fold increased odds of PTDM at 1 year post kidney transplantation. Identifying patients with high pretransplant C-peptide levels may therefore help identify those at risk for PTDM who may benefit from focused preventative and therapeutic interventions and support.

Indexed as

Diabetes MellitusKidney TransplantationAdultCohort StudiesC-PeptideHumansNova ScotiaC-PeptideC-peptidehemoglobin A1chyperglycemiakidney transplantationnodatobesitypost-transplant diabetesrisk factorstransplantation

Identifiers

PMID36514718
PMCPMC9717663
OpenAlexW4283712187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.